Theodore Karrison Selected Research

Squamous Cell Carcinoma of Head and Neck

1/2020	A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study.
7/2016	WHSC1L1 drives cell cycle progression through transcriptional regulation of CDC6 and CDK2 in squamous cell carcinoma of the head and neck.
7/2006	A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Theodore Karrison Research Topics

Disease

35	Neoplasms (Cancer) 01/2022 - 08/2002
8	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 05/2004
7	Adenocarcinoma 01/2022 - 08/2004
6	Renal Cell Carcinoma (Grawitz Tumor) 01/2017 - 10/2003
5	Neoplasm Metastasis (Metastasis) 01/2022 - 01/2016
5	Disease Progression 01/2022 - 04/2005
5	Fatigue 01/2020 - 05/2004
5	Kidney Neoplasms (Kidney Cancer) 01/2017 - 10/2003
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 07/2006
4	Lymphoma (Lymphomas) 01/2019 - 09/2004
4	Lung Neoplasms (Lung Cancer) 01/2018 - 01/2010
4	Leukemia 01/2014 - 04/2002
3	Pain (Aches) 11/2022 - 07/2014
3	Melanoma (Melanoma, Malignant) 01/2021 - 06/2013
3	Squamous Cell Carcinoma of Head and Neck 01/2020 - 07/2006
3	Hypertension (High Blood Pressure) 01/2017 - 10/2003
3	Exanthema (Rash) 01/2016 - 03/2008
3	Carcinoma (Carcinomatosis) 01/2016 - 11/2002
3	Pancreatic Neoplasms (Pancreatic Cancer) 12/2015 - 11/2005
3	Neutropenia 08/2014 - 04/2004
3	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 02/2014 - 04/2002
3	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2014 - 01/2006
3	Hemolysis 03/2006 - 07/2002
3	Chromosome Aberrations (Chromosome Abnormalities) 01/2006 - 04/2002
2	Breast Neoplasms (Breast Cancer) 01/2020 - 03/2004
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2018 - 03/2012
2	Birth Weight (Birth Weights) 01/2018 - 08/2004
2	Nausea 01/2014 - 05/2013
2	Diarrhea 01/2014 - 03/2008
2	Ovarian Neoplasms (Ovarian Cancer) 01/2012 - 11/2002
2	Congenital Toxoplasmosis 12/2011 - 05/2006
2	Jaundice (Icterus) 07/2002 - 07/2002
1	Drug-Related Side Effects and Adverse Reactions 11/2022
1	Apnea 11/2022
1	Oropharyngeal Neoplasms 01/2022
1	Pneumonia (Pneumonitis) 01/2022
1	Circulating Neoplastic Cells 01/2022
1	Carcinogenesis 11/2020

Drug/Important Bio-Agent (IBA)

7	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 08/2002
5	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2006
5	Proteins (Proteins, Gene)FDA Link 01/2019 - 08/2002
5	Pharmaceutical PreparationsIBA 07/2016 - 02/2009
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2017 - 05/2004
4	Gemcitabine FDA Link 12/2015 - 10/2003
4	Bevacizumab (Avastin)FDA Link 01/2013 - 11/2005
3	AndrogensIBA 01/2022 - 07/2009
3	AntigensIBA 01/2017 - 04/2008
3	Phosphotransferases (Kinase)IBA 02/2016 - 01/2010
3	Biological ProductsIBA 12/2015 - 12/2004
3	Irinotecan (Camptosar)FDA LinkGeneric 08/2014 - 04/2004
3	Sorafenib (BAY 43-9006)FDA Link 01/2013 - 10/2008
3	BilirubinIBA 03/2006 - 07/2002
2	IpilimumabIBA 01/2022 - 01/2021
2	pembrolizumabIBA 01/2021 - 12/2020
2	AntibodiesIBA 01/2021 - 12/2011
2	CarcinogensIBA 11/2020 - 09/2004
2	temsirolimus FDA Link 01/2020 - 11/2010
2	Docetaxel (Taxotere)FDA Link 01/2020 - 02/2016
2	Trastuzumab (Herceptin)FDA Link 01/2020 - 01/2020
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 03/2004
2	Ethanol (Ethyl Alcohol)IBA 01/2018 - 01/2017
2	Metformin (Glucophage)FDA LinkGeneric 01/2018 - 01/2012
2	saracatinibIBA 02/2016 - 06/2013
2	PlatinumIBA 01/2016 - 04/2005
2	LigandsIBA 12/2015 - 01/2011
2	Ethylnitrosourea (N-Ethyl-N-nitrosourea)IBA 01/2014 - 09/2004
2	Peptides (Polypeptides)IBA 01/2014 - 01/2013
2	Formaldehyde (Formol)FDA Link 01/2014 - 01/2010
2	ParaffinIBA 01/2014 - 01/2010
2	ixabepilone (BMS 247550)FDA Link 05/2013 - 04/2007
2	VaccinesIBA 01/2013 - 12/2011
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2013 - 07/2011
2	Fluorouracil (Carac)FDA LinkGeneric 01/2013 - 10/2003
2	Erlotinib Hydrochloride (CP 358,774)FDA Link 03/2012 - 03/2008
2	Angiogenesis InhibitorsIBA 10/2008 - 05/2004
2	O(6)-benzylguanineIBA 04/2005 - 08/2002
2	Hormones (Hormone)IBA 05/2004 - 01/2004
1	Succinylcholine (Suxamethonium Chloride)FDA LinkGeneric 11/2022
1	DeoxyriboseIBA 01/2022
1	Nucleic AcidsIBA 01/2022
1	Mifepristone (RU 486)FDA Link 01/2022
1	enzalutamideIBA 01/2022
1	NivolumabIBA 01/2022
1	Androgen Receptors (Androgen Receptor)IBA 01/2022
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2022
1	Gonadotropin-Releasing Hormone (GnRH)FDA Link 01/2021
1	bicalutamide (Casodex)FDA LinkGeneric 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Estrogens (Estrogen)FDA Link 11/2020
1	ElectrolytesIBA 01/2020

Therapy/Procedure

25	Therapeutics 01/2022 - 04/2002
9	Drug Therapy (Chemotherapy) 01/2022 - 11/2002
6	Radiotherapy 01/2021 - 07/2003
4	Castration 01/2022 - 07/2009
4	Immunotherapy 01/2021 - 04/2008
2	Perioperative Care 11/2022 - 01/2022
2	Critical Care (Surgical Intensive Care) 11/2022 - 01/2022
2	Induction Chemotherapy 01/2022 - 01/2022
2	Drug Tapering 01/2022 - 01/2016
2	Prostatectomy (Retropubic Prostatectomy) 01/2016 - 07/2014